In early studies, denosumab, a fully-human monoclonal antibody with high affinity and specificity for human RANKL, inhibits bone resorption in patients with advanced cancer [98,99,100], including those with failed bisphosphonate treatment [99]. The gene discussed is TNFSF11; the disease is cancer.